We observed a trend toward a lower glycoPER in UNC0642 treated (Fig. 5D), SESN2 (Fig. 5E), and EHMT2 (Supplementary Fig. 5F and 5H) deprived T-ALL cells versus DMSO or non-targeting control, confirming a decrease in overall glycolysis following G9a inhibition. The gene discussed is SESN2; the disease is acute lymphoblastic leukemia.